Fresh analysis suggests that patients who stop using new slimming jabs like Mounjaro or Wegovy tend to recover shed pounds far faster than those who halt conventional lifestyle plans.
Findings released in a leading medical journal points out that while obese people often shed a large proportion of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users purchasing these treatments should be aware of the danger of quick weight regain when the therapy concludes," warns expert Dr. Susan Jebb.
This pace of regain implies a return to starting mass within about 18 months.
Comparing Approaches
The study, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists note that individuals who lose weight through lifestyle changes alone generally have a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Doctors propose the mechanism of the jabs explains the accelerated rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone concentrations several times higher than normal could lead to the system to produce less of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating far more likely."
An Ongoing Condition?
Health authorities suggest the jabs for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts say that, considering the high risk of relapse, the therapy might need to be life-long.
This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the long-term nature of excess weight," akin to managing diseases like diabetes.
User Testimonies
Users who have discontinued the medication explain a intense return of appetite.
"I experienced a trigger activating and I was suddenly starving," said a patient.
This difficulty is compounded if users have not adopted lasting lifestyle or habit modifications during therapy.
Growing Adoption
Figures show that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial.
- Adoption is more common among women than males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, experts emphasize that while the jabs are potent agents for shedding pounds, they are not a permanent cure and long-term success hinges on combined behavioural management.